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Abstract 
Background: With the increasing trend of metabolic syndrome (MetS) and atherothrombotic stroke (which can 
manifest as stroke lesion multiplicity), studies on the association between MetS and the clinical aspects of athero‑
thrombotic stroke are of great interest. The present study aimed to investigate the association between MetS and 
multiple atherothrombotic strokes in patients with intracranial atherothrombotic stroke.
Methods: A retrospective study based on medical charts was conducted among patients (n = 202: 137 men/65 
women) who were symptomatically admitted to the hospital with the first‑ever atherothrombotic stroke. For the 
occurrence of multiple lesions of stroke, odds ratio [OR: 95 % confidence interval (CI)] of MetS or its respective compo‑
nents was calculated using logistic regression models.
Results: Fifty‑one percent of the men and 38 % of women with stroke presented multiple regions. MetS was a sig‑
nificant factor that was associated with an increased risk of multiple regions in women [OR 4.3 (95 % CI 1.4–13.5)], but 
not in men. According to the components of MetS, dyslipidemia was a significant factor that was positively associated 
with multiple regions in both men [OR 2.0 (95 % CI 1.1–3.7)] and women [OR 3.2 (95 % CI 1.1–9.1)].
Conclusion: MetS may be pathophysiologically associated with intracranial atherothrombotic stroke multiplicity in 
women in particular. Future studies are warranted to confirm the findings.
Keywords: Insulin resistance, Obesity, Triglyceride, HDL‑cholesterol, Dyslipidemia, Ischemic stroke
© 2015 Kotani et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Metabolic syndrome (MetS) consists of metabolic abnor-
malities, such as obesity, high blood pressure (BP), 
hyperglycemia and dyslipidemia (high triglyceride (TG)/
high-density lipoprotein cholesterol (HDL-C)) [1, 2]. 
MetS is considered to be a risk factor of vascular diseases 
[1, 2]. Therefore, the elucidation of the clinical relevance 
of MetS in vascular medicine is of importance.
Stroke is one of the vascular diseases, and a better 
understanding of the pathophysiology of stroke is crucial 
given its frequency and global socio-medical burden 
[3, 4]. There has been evidence of a positive association 
between MetS and the prevalence/morbidity of stroke 
[5–10]. Of note, intracranial atherothrombotic stroke has 
gradually increased among ischemic stroke patients with 
the epidemic of MetS in Japan [11]. In fact, a few stud-
ies have reported a positive association between MetS 
and atherothrombotic stroke [7, 12–14]. With the grow-
ing concern of studies for atherothrombotic stroke [11], 
the association between MetS and the clinical aspects of 
atherothrombotic stroke should be further explored.
Atherothrombosis has a biological characteristic to 
lead to multi-bed vascular disorders [15]. Carotid athero-
sclerosis, reflective of generalized atherosclerotic mani-
festations, is reported to increase the risk of vascular 
events in relation to MetS [16]. It is of interest to study 
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the association between MetS and atherothrombotic 
stroke legion multiplicity; however, there is a paucity of 
such data. Therefore, the present study aimed to investi-
gate the association between MetS and multiple athero-
thrombotic strokes in in-patients who were admitted to 
the hospital with the first-ever stroke.
Methods
We conducted a retrospective study through an analysis 
of medical charts (from 2003 to 2006) of patients who 
were admitted to our hospital with defined intracranial 
atherothrombotic stroke. The included patients were 
limited to those with a diagnosis of the first-ever symp-
tomatic stroke. The diagnosis of atherothrombotic stroke 
was made according to the diagnostic criteria of the 
National Institute of Neurological Disorders and Stroke 
by neurological specialists [17]. That is, it was diagnosed 
in cases with infarcts greater than 1.5 cm in diameter of 
a major brain and/or branch cortical artery on imaging (a 
computed tomography and/or magnetic resonance imag-
ing) as possible origins under clinical symptoms of neu-
rological deficits [17]. Strokes in patients with a source of 
embolus, such as atrial fibrillation, moderate-to-severe 
valvular heart disease or intra-carotid/cardiac thrombus, 
were excluded as having a definite or possible cardioem-
bolic stroke [17]. Strokes in patients with an undeter-
mined etiology despite an extensive evaluation were 
also excluded [17]. The study was approved by the Ethics 
Committee of Kyoto Medical Center.
A total of 202 patients (137 men and 65 women) were 
enrolled in the study. The clinical data on the compo-
nents of MetS and stroke multiplicity in the patients was 
collected based on the description of the medical records. 
Like the National Cholesterol Education Program Adult 
Treatment Panel III [1] (the criterion level for obesity 
and low HDL-C was modified for Japanese people [2, 
18]), the patients were diagnosed as having MetS when 
the patients had at least three components of MetS. The 
components were obesity (a body mass index ≥25  kg/
m2 [2] ), high BP (systolic BP ≥130 mmHg, diastolic BP 
≥85  mmHg and/or the use of antihypertensive drugs), 
hyperglycemia (fasting plasma glucose ≥110 mg/dL and/
or the use of glucose-lowering drugs), high TG (fasting 
serum triglyceride ≥150 mg/dL and/or the use of triglyc-
eride-lowering drugs) and low HDL-C (fasting serum 
HDL-C <40 mg/dL [18] ). The components of MetS were 
according to the laboratory data and/or the description 
in medical records (e.g., if glucose intolerance was clearly 
described in the charts, it was treated as being within the 
hyperglycemic criteria).
The differences between the groups were examined by 
an independent t test or the Chi square test. For the out-
come variable (having multiple lesions of stroke), odds 
ratio [OR: 95 % confidence interval (CI)] of the explana-
tory variables (MetS and its components) was calcu-
lated using crude and adjusted logistic regression model 
analyses. In the logistic regression models, high TG 
and low HDL-C were treated as a dyslipidemic compo-
nent because few patients had low HDL-C (this is often 
seen in Japanese people) and the potential collinearity 
of low HDL-C with high TG (which mirrors the biologi-
cal nature). The statistical analyses were also performed 
according to gender. A P value < 0.05 was considered to 
be statistically significant.
Results
Table  1 shows the clinical characteristics of study 
patients. In men, 51 % of the stroke cases presented mul-
tiple regions, while 38  % of women presented multiple 
regions. There was a significantly higher prevalence of 
obesity and hyperglycemia in women than in men. In 
men, the group with multiple legions had a significantly 
higher prevalence of dyslipidemia (high TG in particular) 
than the group with a single region. In women, the group 
with multiple legions had a significantly higher preva-
lence of dyslipidemia (high TG in particular) and MetS 
than the group with a single region.
Table 2 shows the OR (95 % CI) of MetS for multiple 
lesions. Crude and age-adjusted logistic regression model 
analyses revealed that MetS was a significant factor 
(approximately 4-fold) that was positively associated with 
multiple regions in women, but not men.
Table 3 also shows the OR (95 % CI) of each component 
of MetS for multiple lesions. The crude and multivariate-
adjusted logistic regression model analyses revealed that 
dyslipidemia was a significant factor (approximately 2- 
to 3-fold) that was positively associated with multiple 
regions in both men and women.
Discussion
In the present study, MetS showed a significant positive 
association with multiple lesions of intracranial athero-
thrombotic stroke in women, but not men, who were 
in-patients admitted to the hospital with the first-ever 
stroke. The observation that MetS may be an underly-
ing entity for the formation of intracranial stroke mul-
tiplicity with a possible gender bias is new information. 
Atherothrombotic stroke is considered a treatable target 
[11], while in patients suffering from multiple lesions of 
stroke, it may lead to multiple neurological and/or cog-
nitive dysfunctions [19, 20]. Thus, the treatment of MetS 
can be significant for preventing atherothrombotic stroke 
multiplicity and subsequent dysfunctions in women in 
particular.
A positive association between MetS and athero-
thrombotic stroke has been reported [7, 12–14], and 
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the etiopathological mechanisms of atherothrombosis 
(e.g., via vasomotor reactivity impairment, insulin resist-
ance, inflammation, oxidative stress, platelet activation 
and hypercoagulation) have been proposed [15, 20–24]. 
Under the etiopathology, atherothrombotic stroke may 
suddenly occur in multiple lesions, and/or the repeated 
stroke formation may be unnoticed in some cases whose 
lesions are multiple, like a silent brain infarct [25, 26]. 
Gender differences exist in the clinical features of MetS, 
stroke and their association thereof [11, 27–29]; that is, 
the influences of MetS on stroke may be greater in Japa-
nese women than in men [27, 28]. According to these 
literature findings, the associations among MetS and 
atherothrombotic stroke multiplicity observed in the pre-
sent survey appear to be plausible. On the other hand, 
though the impact of MetS on multiple lesions in men 
was not significant and weaker than that in women, the 
OR level was over 1.5 (Table 2) and confirmation may be 
repeatedly required in men. Mutifaceted studies includ-
ing etiopathological factors and larger samples in both 
genders will be necessary to understand the findings.
The clinical significance of MetS or each compo-
nent of MetS on the atherosclerotic outcomes is poorly 
understood [30–32]. In the present study, the analysis of 
each component of MetS with multiple lesions showed 
Table 1 Clinical characteristics of the patients
Independent t-test, P1: single vs. multiple in men, P2: single vs. multiple in women, P3: all men vs. all women.
BP blood pressure, TG triglyceride, HDL high-density lipoprotein, MetS metabolic syndrome.
Men P1 Women P2 P3
All Single Multiple All Single Multiple
Number, n 137 (100 %) 67 (49 %) 70 (51 %) – 65 (100 %) 40 (62 %) 25 (38 %) – 0.09
Age (years) 68 ± 9 67 ± 11 69 ± 7 0.17 70 ± 10 70 ± 12 69 ± 7 0.62 0.20
Obesity 28 (20 %) 14 (21 %) 14 (20 %) 0.90 24 (37 %) 12 (30 %) 12 (48 %) 0.14 0.01*
High BP 101 (74 %) 49 (73 %) 52 (74 %) 0.88 41 (63 %) 24 (60 %) 17 (68 %) 0.52 0.12
Hyperglycemia 64 (47 %) 26 (39 %) 38 (54 %) 0.07 42 (65 %) 23 (58 %) 19 (76 %) 0.13 0.02*
High TG/low HDL‑C 70 (51 %) 28 (42 %) 42 (60 %) 0.03* 33 (51 %) 16 (40 %) 17 (68 %) 0.03* 0.97
 High TG 66 (48 %) 26 (39 %) 40 (57 %) 0.03* 31 (48 %) 14 (35 %) 17 (68 %) 0.01* 0.94
 Low HDL‑C 7 (5 %) 3 (4 %) 4 (6 %) 0.74 7 (8 %) 3 (8 %) 4 (16 %) 0.28 0.14
MetS 25 (18 %) 10 (15 %) 15 (21 %) 0.33 19 (29 %) 7 (18 %) 12 (48 %) 0.01* 0.08
Table 2 Odds ratio (95  % confidence interval) of  MetS 
for multiple lesions
Variable All Men Women












Table 3 Odds ratio (95 % confidence interval) of each component of MetS for multiple lesions
Multivariate-adjusted model: age, obesity, high blood pressure, hyperglycemia and high TG/low HDL-C were entered into the model as variables for multiple lesions.
MetS metabolic syndrome, TG triglyceride, HDL high-density lipoprotein.
Variable All Men Women
Crude
 Age (years) 1.0 (1.0–1.0, p = 0.52) 1.0 (1.0–1.1, p = 0.14) 1.0 (0.9–1.0, p = 0.62)
 Obesity 1.2 (0.6–2.2, p = 0.62) 0.9 (0.4–1.8, p = 0.77) 2.2 (0.8–6.1, p = 0.15)
 High blood pressure 1.2 (0.7–2.3, p = 0.49) 1.4 (0.7–2.8, p = 0.31) 1.4 (0.5–4.1, p = 0.52)
 Hyperglycemia 1.8 (1.0–3.1, p = 0.04*) 1.5 (0.8–2.8, p = 0.16) 2.3 (0.8–7.1, p = 0.13)
 High TG/low HDL‑C 2.3 (1.3–4.1, p < 0.01*) 2.0 (1.1–3.7, p = 0.02*) 3.2 (1.1–9.1, p = 0.03*)
Multivariate‑adjusted
 Age, years 1.0 (1.0–1.0, p = 0.33) 1.0 (1.0–1.1, p = 0.05) 1.0 (0.9–1.0, p = 0.56)
 Obesity 1.1 (0.6–2.2, p = 0.69) 1.0 (0.4–2.3, p = 0.95) 1.9 (0.6–5.8, p = 0.27)
 High blood pressure 1.2 (0.6–2.3, p = 0.54) 1.0 (0.4–2.2, p = 0.99) 1.4 (0.5–4.3, p = 0.56)
 Hyperglycemia 1.7 (0.9–3.1, p = 0.06) 1.9 (0.9–3.9, p = 0.07) 2.2 (0.7–7.5, p = 0.20)
 High TG/low HDL‑C 2.5 (1.4–4.4, p < 0.01*) 2.6 (1.2–5.4, p = 0.01*) 3.0 (1.0–8.9, p = 0.046*)
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that dyslipidemia in particular (such as high TG and/or 
low HDL-C [33]) was positively associated with multi-
ple lesions in both genders. Such a significant influence 
of dyslipidemia on stroke can be supported by previous 
studies [11, 34], although these studies did not examine 
stroke multiplicity. In addition to the treatment of MetS, 
a consideration of atherogenic dyslipidemia [33] could 
be particularly pivotal when subjects do not necessarily 
manifest a complete MetS phenotype.
There are several limitations associated with this 
study. The study had a retrospective design based on 
clinical data obtained from medical records. Although 
the multiple lesions detected in the present study could 
include old infarcts, the clear discrimination between 
new and old infarcts was not always made (it was dif-
ficult to discriminate them based on a retrospective 
description of medical records). The number of multi-
ple lesions may also be useful information; however, it 
could not completely be collected in this survey. The 
additional information (e.g., serum low-density lipo-
protein cholesterol, smoking and alcohol intake) was 
not fully collected for all patients. Information bias may 
therefore affect the study results. The study was con-
ducted in a single hospital, which could lead to selec-
tion bias. Furthermore, there may be ethnic disparities 
in the relevance of MetS on stroke multiplicity [10] and 
the definition of MetS itself may affect the results [14, 
35]. These issues should be addressed in future studies 
with prospective and multicentric designs with various 
populations.
In summary, MetS may have a pathophysiology associ-
ated with intracranial atherothrombotic stroke multiplic-
ity in women in particular. Future studies are warranted 
to confirm the findings.
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